Holen Sie sich die Stockscreener-App
3.92
91.22%
1.87
Handel nachbörslich:
3.99
0.07
+1.79%
Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten
Entera Bio Ltd. announced that it expects to receive $274.999977 million in funding from a group of investors - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entera Bio raises $275m for Phase III osteoporosis drug trialGlobes - Globes - Israel Business News
Entera Bio raises $275 million in private placement for phase 3 - Investing.com
ENTX Stock Explodes Higher As Traders Pounce On Breakout - StocksToTrade
Entera Bio stock surges on $275M private placement - Investing.com
Entera Bio raises $275 million in private placement - Investing.com
Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement - TradingView
Entera Bio raises $275 million in private placement By Investing.com - Investing.com Canada
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement - GlobeNewswire
ENTX|Entera Bio Ltd|Price:3.930|Chg%:+1.880 - TradingKey
Entera Bio Ltd (ENTX) Cash Flow - TradingKey
Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entera Bio Ltd (ENTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ENTX|Entera Bio Ltd|Price:3.830|Chg%:+1.780 - TradingKey
ENTX|Entera Bio Ltd|Price:2.050|Chg%:-0.080 - TradingKey
Entera Bio Ltd (ENTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entera Bio Leads Our Top 3 Penny Stocks To Consider - Sahm
Entera Bio Ltd. (ENTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know - Yahoo Finance
Entera Bio Expands Share Authorization and Equity Plans - TipRanks
Entera Bio Ltd. Approves Director Compensation, Share-Based Plans, and Capital Increase at 2026 Annual Meeting - Minichart
Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs - Stock Titan
Entera Bio shareholders approve authorized share increase at annual meeting - Bitget
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - TipRanks
After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - Benzinga
Entera Bio (ENTX) Slips Slightly as Stock Hovers Near Key Support LevelLast Point Resistance - dars.gov.et
America’s Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) - TipRanks
America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) - Benzinga
ENTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseEarnings Volatility Report - dars.gov.et
Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus - TradingView
Price to earnings forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to earnings forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to EBIT forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Price to book forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Entera Bio Ltd. Actuals & Estimates (HAM:5DT) - TradingView
ENTX Forecast — Price Target — Prediction for 2027 - TradingView
5DT Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback - Investing.com UK
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewswire Inc.
3 Promising Penny Stocks With Market Caps Under $600M - simplywall.st
ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline - timothysykes.com
ENTX stock on track for best day in over 5 years — what’s driving the rally? - MSN
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally? - Yahoo Finance
FDA backs Entera Bio’s 750-patient osteoporosis trial for EB613 - Stock Titan
With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For - TipRanks
Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback - marketscreener.com
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - The Manila Times
Entera Bio Receives Positive FDA Feedback on 12-Month - GlobeNewswire
Entera Bio gets FDA nod for Phase 3 trial of EB... - Pluang
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):